# US 2026/0076908 A1 · Plurality of tasquinimod particles and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076908 A1
- Document ID: US20260076908A1
- Status: Published application
- Kind: A1
- Application number: 19/399,224
- Filed: 2025-11-24
- Published: 2026-03-19
- Earliest claimed: 2021-05-25
- Assignees: Active Biotech AB
- Applicants: Active Biotech AB
- Inventors: Hans Wännman
- Web page: https://patentgrep.com/patent/US20260076908A1

## CPC

- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 31/4704: 2-Quinolinones, e.g. carbostyril
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A plurality of particles of tasquinimod in free base form or as a pharmaceutically acceptable salt, the particles having a D(v,0.9) of at most 30 μm and a D(v,0.5) of at most 15 μm. A pharmaceutical composition comprising the particles and preferably one or more pharmaceutically acceptable excipients. A pharmaceutical dosage unit. The particles, composition and dosage unit are useful in the treatment of cancer.

## Claims

### Claim 1

A method for the treatment of a hematologic cancer by administering, to a mammal in need of such treatment, a plurality of particles comprising tasquinimod in free base form or as a pharmaceutically acceptable salt, the particles having a D(v,0.9) of at most 25 μm and a D(v,0.5) of at most 15 μm.

### Claim 2 (depends on 1)

The method of claim 1, wherein the particles have a D(v,0.5) in the range of 2 to 10 μm.

### Claim 3 (depends on 1)

The method of claim 1, wherein the treatment comprises administering the plurality of particles in a formulation comprising the particles in an amount of 0.1 to 10% by weight of the formulation and one or more pharmaceutically acceptable excipients.

### Claim 4 (depends on 1)

The method of claim 1, wherein the treatment comprises administering the plurality of particles orally to the mammal.

### Claim 5 (depends on 1)

The method of claim 1, wherein the treatment comprises administering the plurality of particles in a capsule or tablet.

### Claim 6 (depends on 1)

The method of claim 1, wherein the treatment comprises administering the plurality of particles in an immediate-release pharmaceutical dosage unit.

### Claim 7 (depends on 1)

The method of claim 1, wherein the treatment comprises administering the plurality of particles in an immediate-release capsule.

### Claim 8 (depends on 1)

The method of claim 1, wherein the treatment comprises administering the plurality of particles in an amount in the range of 0.1 to 4 mg/day.

### Claim 9 (depends on 1)

The method of claim 1, wherein the treatment comprises administering the plurality of particles 1-3 times per day.

### Claim 10 (depends on 1)

The method of claim 1, wherein the hematologic cancer is multiple myeloma.

### Claim 11 (depends on 1)

The method of claim 1, wherein the hematologic cancer is lymphoma.

### Claim 12 (depends on 1)

The method of claim 1, wherein the hematologic cancer is leukemia.

### Claim 13 (depends on 1)

The method of claim 1, wherein the hematologic cancer is acute lymphoblastic leukemia or acute myeloid leukemia.

### Claim 14 (depends on 1)

The method of claim 1, wherein the hematologic cancer is myelodysplastic syndrome.

### Claim 15 (depends on 1)

The method of claim 1, wherein the hematologic cancer is a myeloproliferative neoplasm.

### Claim 16 (depends on 15)

The method of claim 15, wherein the myeloproliferative neoplasm is selected from the group consisting of myelofibrosis, essential thrombocythemia, polycythemia vera, chronic neutrophilic leukemia, chronic myelogenous leukemia, acute myelogenous leukemia, chronic eosinophilic leukemia and mastocytosis.

### Claim 17 (depends on 15)

The method of claim 15, wherein the myeloproliferative neoplasm is selected from the group consisting of myelofibrosis, essential thrombocythemia, polycythemia vera, chronic neutrophilic leukemia, chronic eosinophilic leukemia and mastocytosis.

### Claim 18 (depends on 15)

The method of claim 15, wherein the myeloproliferative neoplasm is selected from the group consisting of myelofibrosis, essential thrombocythemia and polycythemia vera.

### Claim 19 (depends on 15)

The method of claim 15, wherein the myeloproliferative neoplasm is myelofibrosis.

### Claim 20 (depends on 1)

The method of claim 1, wherein the treatment is a combination therapy including administration of one or more additional drugs.
